证券代码：688067 证券简称：爱威科技 公告编号： 2025-036 爱威科技股份有限公司董事会 2025 年 9 月 13 日 关于参加 2025 年湖南辖区上市公司投资者网上集体接 待日暨半年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，爱威科技股份有限公司（以下简称"公司"） 将参加由湖南证监局、湖南省上市公司协会与深圳市全景网络有限公司联合举办的 "资本聚三湘 楚光耀新程一一 2025 年湖南辖区上市公司投资者网上集体接待日暨 半年度业绩说明会"活动，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （https://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP,参 与本次互动交流，活动时间为 2025 年 9 月 19 曰（星期五）14：00-17：00。届时公 司高管将在线就公司 2024 年至 2025 半年度业绩、公司治理、发展战略、经营状况、 融资计划、股权激励和可持续发展等 ...

Overview - The global infertility rate is rising, leading to increased demand for assisted reproductive technology (ART) and driving the growth of the reproductive medical equipment market in China [1][13] - Changing fertility concepts, delayed childbearing age, and heightened awareness of reproductive health are expanding the market opportunities for reproductive medical devices [1][13] - The aging population and government encouragement for having more children are further stimulating demand for reproductive medical equipment [1][13] - The market size of China's reproductive medical equipment industry is projected to reach 9.69 billion yuan in 2024, with a year-on-year growth of 9.86% [1][13] Market Policies - The Chinese government has issued various policies to support the development of the medical device industry, including reproductive medical equipment [7] - Policies aim to strengthen management, enhance innovation, and promote high-quality development in the medical device sector [7] Industry Chain - The upstream of the reproductive medical equipment industry includes suppliers of chemical materials, biological medical materials, electronic components, and software systems [9] - The midstream involves the research, design, and production of reproductive medical devices [9] - The downstream consists of public hospitals, private reproductive centers, and patients who benefit from these medical devices [9][11] Competitive Landscape - Historically, imported brands dominated the high-end market of reproductive medical devices in China, but domestic companies are increasingly closing the technology gap [13][14] - By 2024, domestic reproductive medical devices are expected to account for 55.11% of the market share, indicating a shift from reliance on imports to domestic alternatives [13][14] Company Analysis - Suzhou Beikang Medical Co., Ltd. focuses on reproductive health product development and achieved a revenue of 299 million yuan in 2024, with a gross profit margin of 45.54% [14][15] - Awei Technology Co., Ltd. specializes in clinical medical testing equipment and achieved a revenue of 203 million yuan in 2024, with 97.74% coming from medical device sales [15] Development Trends - Future advancements in reproductive medical devices will focus on greater intelligence, automation, and personalization, driven by technologies like gene editing and artificial intelligence [15][16] - Domestic companies are expected to continue improving their technological capabilities and market recognition, leading to an accelerated process of domestic substitution in the market [15][16]

爱威科技股份有限公司 2025 年第一次临时股东大会会议资料 爱威科技股份有限公司 2025年第一次临时股东大会会议资料 | 2025年第一次临时股东大会会议须知 | | --- | | 2025年第一次临时股东大会会议议程 . | | 议案一:《关于变更经营范围、取消监事会、修订<公司章程>并办理相应工 | | 商变更登记的议案》 | | 沙安二 | 爱威科技股份有限公司 2025 年第一次临时股东大会会议资料 爱威科技股份有限公司 2025年第一次临时股东大会会议须知 二〇二五年九月 五、股东或股东代理人要求发言时，不得打断会议报告人的报告或其他股东的 发言，在股东大会进行表决时，股东或其代理人不再进行发言。股东或其代理人违 反上述规定，会议主持人有权加以拒绝或制止。 1 爱威科技股份有限公司 2025 年第一次临时股东大会会议资料 六、主持人可安排公司董事、监事、高级管理人员回答股东或股东代理人所提 问题。对于可能将泄露公司商业秘密及/或内幕信息，损害公司、股东共同利益的提 问，主持人或其指定有关人员有权拒绝回答。 为维护全体股东的合法权益，确保股东大会的正常秩序和议事效率，保证大会 的顺利进行，根据《 ...

Financial Performance - The company reported a total revenue of 110 million yuan for the first half of 2025, representing a year-on-year increase of 12.7% [1] - The net profit attributable to shareholders reached 14.0554 million yuan, up 21.16% year-on-year [1] - The gross profit margin was 56.34%, a slight decrease of 0.63% compared to the previous year, while the net profit margin increased by 7.51% to 12.83% [1] - The total of selling, administrative, and financial expenses was 37.2037 million yuan, accounting for 33.96% of revenue, down 6.17% year-on-year [1] - Earnings per share rose to 0.21 yuan, a 23.53% increase year-on-year [1] Business Model and Market Position - The company primarily relies on research and development and marketing to drive its performance [3] - It is a leader in the automation of urine analysis and has a significant market share in this segment, with competitors including Dirui, Mindray, and others [5] - The company has begun to focus on the consumer healthcare market, launching various POCT products aimed at women's health, child health, and other areas, indicating a potential growth direction [6] Technology and Innovation - The company is a pioneer in applying artificial intelligence and machine vision technology to medical urine specimen analysis, significantly improving testing accuracy and efficiency [7] - It has developed a large clinical specimen training database over 25 years, enhancing its algorithm for specimen recognition [7] Future Plans - The company is considering new projects and potential mergers and acquisitions to drive growth, as indicated in its 2024 annual report [8]

Group 1 - The Supervisory Board of the company held its fifth meeting on August 28, 2025, with all three members present, and the meeting complied with relevant laws and regulations [1][2]. - The Supervisory Board approved the company's 2025 semi-annual report, confirming that the report's preparation and review processes adhered to legal requirements and accurately reflected the company's financial status and operational results [1][2]. - The Supervisory Board also approved a special report on the storage and actual use of raised funds, affirming that the funds were stored in dedicated accounts and used appropriately, with no violations of regulations [2][3]. Group 2 - The Supervisory Board approved a proposal to change the company's business scope, cancel the Supervisory Board, and amend the Articles of Association, which aligns with the latest legal requirements and aims to enhance the company's governance structure [2][3]. - The proposal to cancel the Supervisory Board will be submitted for approval at the company's shareholders' meeting, and until then, the Supervisory Board will continue to fulfill its responsibilities [3].

Group 1 - The company, Awei Technology Co., Ltd., is holding its first extraordinary general meeting of shareholders in 2025 on September 17, 2025, at 14:30 [1][2] - The meeting will be conducted using a combination of on-site and online voting methods, with specific instructions for shareholders on how to participate [1][2] - The agenda includes a non-cumulative voting proposal regarding amendments to the company's articles of association and related business registration [1][2] Group 2 - Shareholders must be registered with China Securities Depository and Clearing Corporation Limited by the close of trading on September 11, 2025, to attend the meeting [3] - Registration for the meeting will take place on September 16, 2025, at the company's office, with specific requirements for both individual and corporate shareholders [3] - The company has provided contact information for inquiries related to the meeting, including addresses and phone numbers [4][8]

Group 1 - The core point of the article is that Aiwei Technology has established a new company, Beijing Aiwei Zhijian Diagnostic Technology Co., Ltd., to enhance its strategic development and market expansion [1] - Aiwei Technology invested 6 million RMB, holding a 60% stake in the new company, while individual Wang Jianzhong contributed intellectual property valued at 4 million RMB for a 40% stake [1] - The investment is expected to strengthen the company's core competitive advantages and align with its strategic development goals, having a positive impact on future operations [1] Group 2 - As of the report, Aiwei Technology has a market capitalization of 1.7 billion RMB [2] - The company's revenue composition for the year 2024 is projected to be 97.74% from medical devices and 2.26% from other businesses [1]

证券代码：688067 证券简称：爱威科技 公告编号：2025-035 爱威科技股份有限公司 关于对外投资设立控股子公司的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、对外投资概述 （一）对外投资的基本情况 基于公司的整体战略发展规划和实际经营需求，公司与自然人王建中共同投 资设立北京爱微智检诊断科技有限公司，其中，公司以自有资金出资人民币 600 1 投资标的名称：北京爱微智检诊断科技有限公司（以下简称"爱微智 检"） 投资金额：爱微智检注册资本人民币 1,000 万元，其中爱威科技股份 有限公司（以下简称"公司"）以自有资金出资人民币 600 万元，占爱 微智检注册资本的 60%；自然人王建中以知识产权作价出资人民币 400 万元，占爱微智检注册资本的 40%。 根据《上海证券交易所科创板股票上市规则》《公司章程》及相关制度 的规定，本次对外投资在公司总经理审批权限内，并已履行内部决策 程序，无需提交董事会、股东大会审议。 本次对外投资不构成关联交易，亦不构成《上市公司重大资产重组 ...

Core Viewpoint - The company has announced a joint investment with individual Wang Jianzhong to establish Beijing Aiwei Zhijian Diagnostic Technology Co., Ltd, with a registered capital of RMB 10 million [1] Group 1 - The company contributes RMB 6 million in cash, holding a 60% stake in the new entity [1] - Wang Jianzhong contributes intellectual property valued at RMB 4 million, holding a 40% stake [1] - The registration and business license for Aiwei Zhijian were completed on August 28, 2025 [1]

Group 1 - The company announced the approval of multiple proposals, including the 2025 semi-annual report and its summary, during the fifth meeting of the fifth supervisory board [2]